华仁药业2025年业绩预亏，计提商誉减值超4亿元

Core Viewpoint - The company, Huaren Pharmaceutical, is expected to report a significant loss in 2025 due to substantial goodwill impairment related to two subsidiaries, while also expanding its renal business capacity and experiencing executive changes [1][2]. Financial Performance - The company forecasts a net profit attributable to shareholders of between -480 million yuan and -360 million yuan for 2025, primarily due to goodwill impairment of 440 million to 540 million yuan related to subsidiaries Anhui Hengxing Pharmaceutical and Guangxi Yuyuan Pharmaceutical [2] - Excluding the impairment impact, the core business net profit is projected to be between 60 million and 80 million yuan, indicating stabilization in core operations [2]. Company Status - The goodwill impairment stems from unmet performance commitments following the acquisition of Anhui Hengxing Pharmaceutical in 2021, with ongoing litigation regarding a 256 million yuan payment to the original equity transferor, creating uncertainty [3]. - The company plans to enhance capacity, expand channels, and optimize product structure for the involved subsidiaries to gradually improve profitability [3]. Capacity Expansion - In November 2025, the company launched the first production line for peritoneal dialysis solution at its Rizhao factory, increasing annual capacity to 51 million bags, with a second line under testing that will raise total capacity to 62 million bags, reinforcing market supply capabilities [4]. - The renal business remains a strategic focus, with sales and revenue from peritoneal dialysis solutions continuing to grow in 2025 [4]. Executive Changes - In December 2025, a major shareholder, Huaren Century Group, reduced its stake from 7.06% to 6.83%, which the company stated did not affect control or operations [5]. - The company experienced an unexpected change in leadership when Chairman Zhang Li resigned for personal reasons on August 26, with Director Hou Ruipeng assuming responsibilities, described as a personal matter by the company [5]. Strategic Advancement - The company is advancing its "raw materials + formulations + packaging" integrated strategy, enhancing production efficiency through digital upgrades and expanding into high-value product matrices in respiratory and narcotic fields to address pricing pressures from centralized procurement policies [6]. - In 2025, the company obtained multiple product approvals and patents to strengthen its long-term competitiveness [6].